




Corporate Presentation

Aug 2026



Disclaimer



THIS DOCUMENT OR THE INFORMATION CONTAINED HEREIN IS NOT INTENDED TO AND DOES NOT CONSTITUTE ANY OFFER OR INVITATION, SOLICITATION, COMMITMENT OR ADVERTISEMENT OF ANY OFFER FOR SUBSCRIPTION, PURCHASE OR SALE OF ANY SECURITIES, NOR SHALL ANY PART OF THIS DOCUMENT FORM THE BASIS OF OR BE RELIED ON IN CONNECTION WITH ANY CONTRACT OR COMMITMENT WHATSOEVER.

This document is strictly confidential to the recipient only, and may not be copied, reproduced, redistributed, disseminated, or used or disclosed to any other person, or published, in whole or in part, for any other purpose. This document has been prepared by Insilico Medicine Cayman TopCo (the “**Company**”) but without further investigation and cannot be warranted as to its accuracy or completeness. Neither the Company, its joint sponsors and syndicate banks (the “**Syndicates**”), nor any of their respective subsidiaries or affiliates, controlling persons, directors, supervisors, officers, partners, agents, employees, advisers, and representatives have verified independently any or all such information or assumptions made, or there may exist other facts, risks or considerations which might be material concerning the information herein. Accordingly, neither the Company, the Syndicates, nor any of their respective subsidiaries or affiliates, controlling persons, directors, supervisors, officers, partners, agents, employees, advisers, and representatives, make any representation or warranty, expressed or implied, with respect to the information or assumptions contained in this document or on which this document is based, or that the information or assumptions remains unchanged after the issue of this document, and will not accept any loss, liability or responsibility whatsoever for the accuracy or completeness of the information or assumptions on which this document is based.

This document does not have regard to the specific investment objectives, financial situation or particular needs of any specific persons who may receive this document. This document is not to be relied upon as such or used in substitution for the exercise of independent judgment. The recipient must make its own assessment of the relevance, accuracy and adequacy of the information contained or assumptions made in this document prior to entering into any transaction or investment.

Certain data in this document was obtained from external data sources, and the Company has not verified such data with independent sources. Accordingly, the Company, the Syndicates, any of their respective subsidiaries or affiliates, controlling persons, directors, supervisors, officers, partners, agents, employees, advisers, and representatives make no representations as to the accuracy or completeness of that data. Such data involves risks and uncertainties and is subject to change based on various factors. The use of registered trademarks, commercial trademarks and logos or photographic materials within this document are exclusively for illustrative purposes and are not meant to violate the rights of the creators and/or applicable intellectual property laws.

Certain statements are set forth in this document with respect to the Company or other events, including but not limited to opinions and forward-looking statements with respect to the future financial condition and results of operations of the Company and certain plans and objects of the management of the Company. Such statements are based on a number of assumptions, including but not limited to the present business strategies of the Company and other matters beyond the control of the Company, such as the political, social, legal and economic environment in which the Company will operate in the future. Such statements are subject to known and unknown risks, uncertainties and other factors which may cause the actual performance or results of operations of the Company to differ materially from such opinions or forward-looking statements or the views, expressed or implied, contained in this document. No reliance should be placed on such statements, which reflect the view of the management of the Company as at the date of this document. Neither the Company, the Syndicates, any of their respective subsidiaries or affiliates, controlling persons, directors, supervisors, officers, partners, agents, employees, advisers, and representatives shall be obliged in any way to update such opinions or forward-looking statements for any event or circumstances that may occur. In any case, past performance is not necessarily an indication of future results. No representation or warranty, express or implied, is or will be given by Company, the Syndicates, or any of their respective subsidiaries or affiliates, controlling persons, directors, supervisors, officers, partners, agents, employees, advisers, and representatives as to the achievement or reasonableness of, and no reliance should be placed on, any forward-looking statements contained in this document.

This document is for information and reference only and does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities (the “**Securities**”) of the Company in any jurisdiction or an inducement to enter into investment activity nor should it form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. In particular, this document and the information contained herein are not an offer of the securities for sale in the United States and are not for publication or distribution in the United States. The document is being presented to you on the basis that you have confirmed that you are either (i) a qualified institutional buyer (as defined in Rule 144A under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”) or (ii) a non-U.S. person (as defined in Regulation S under the Securities Act). This document is not intended for distribution to persons who are not professional investors (as defined in Schedule 1 to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). This document contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) (the “**CWUMPO**”), or an advertisement or extract from or abridged version of a prospectus within the meaning of section 38B of the CWUMPO or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong. This document does not constitute a prospectus, notice, circular, brochure or advertisement offering to sell or inviting offers to acquire, purchase or subscribe for any securities in Hong Kong or calculated to invite such offers or inducing or intended to induce subscription for or purchase of any securities in Hong Kong. No part of these materials shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

This presentation and the information contained herein are strictly confidential and are being furnished to you solely for your information and for your use only at the presentation to analysts held by the Company. No part of it may be kept by you upon the completion of the presentation. By attending the meeting where this presentation is made or by accepting a copy of this presentation, you agree to be bound by the foregoing limitations and to maintain absolute confidentiality regarding the information disclosed in this presentation and in particular, you: (a) acknowledge and confirm that you have read, and agree to, the restrictions and observations set out in the research guidelines from Cooley HK (the “**Research Guidelines**”); (b) agree and undertake not to seek from the Company, its directors or its advisers, whether directly or indirectly, any material information including forward-looking information (whether qualitative or quantitative) concerning the Company that is not: (i) reasonably expected to be included in the prospectus to be issued by the Company; or (ii) publicly available; and (c) are deemed to have agreed to and represented to the Company and the representatives the matters set out in the Research Guidelines.


THE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR ANY OTHER JURISDICTION AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT IN CERTAIN TRANSACTIONS EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. NO PUBLIC OFFERING OF ANY SUCH SECURITIES WILL BE MADE IN THE UNITED STATES OR IN ANY OTHER JURISDICTION WHERE SUCH AN OFFERING IS RESTRICTED OR PROHIBITED.



SECTION 1

Company Strategy

Traditional Drug R&D Takes >10 Years and >\$2B*



* Modified from Paul et al, How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 2010

** Based on interviews with the pharmaceutical industry executives


Evaluating AIDD Companies

Metrics to evaluate an AIDD company: The Potential → The Proof

$$PI_{AI} = \frac{V_{out} \times N_{target} \times N_{mol} \times P_{trans}}{C_{total} \times T_{avg}}$$

AI Productivity Index → PI_{AI}
 Out-Licensing Value → V_{out}
 Target Novelty → N_{target}
 Molecule Novelty → N_{mol}
 Transition Probability → P_{trans}
 Total Cost → C_{total}
 Average Time → T_{avg}

Early-stage Evaluation




Compute Power



Raw Data Volume



Teams & Talents



Algorithm Patents

Mature-stage Evaluation



0 to PCC Time



Cost per PCC




Target Novelty



Engine Scalability




Out-licensing Success /Clinical Progression



Insilico Medicine Stats

12-18 months
Average time to PCC



\$3-5M
Average cost to PCC



TNIK, PHD1/2, QPCTL
and more



32
Total PCC



17
BD Deals



1 Phase III Trial



Leveraging the Flywheel Effect to Position Our AI Platform at the Forefront

PHARMA.AI Software Platform

Continuous improvement and expansion on capabilities and accuracy of PandaOmics, Generative Chemistry and Alchemy etc.

2025

Launched Nach01, MDFlow, MolSpace etc.


2024

Launched Model Training, Retrosynthesis, Generative Biologics, DORA etc.

2023

Full upgradation on Pharma.AI Platform

Generated 1000+ benchmarks during PCC development:
PCC essentials, medicinal chemistry, synthetic chemistry, target identification, clinical trial outcome, longevity



Proprietary data to improve AI

Drug Discovery and Development

- 1 Phase III trial ongoing
- ✓ Completed 1 Phase IIa trial
- 2 Phase II trial ongoing
- 7 Phase I trial ongoing

2025 – 2026 YTD

10 PCC

2024

5 PCC

2023

6 PCC

The background is a dark, futuristic scene with glowing green and yellow circuit lines. A central square chip is highlighted with a bright yellow glow. Scattered around are various molecular models, some with blue and white spheres, and others with green and yellow spheres. The overall aesthetic is high-tech and digital.

SECTION 2

AI Platform


World's Leading Generative AI-powered Drug Discovery and Development Platform with End-to-end Capabilities

Biology42




PandaOmics

Discover and Prioritize Novel Targets



Generative Biologics

Discover and Optimize Novel Biomolecules



Life Star 2

Automated Lab Operating Environment

AI Life Models



Precious1GPT

Multimomics Age Prediction & Target ID



Precious2GPT


Multimodal Multimomics Biological Data Synthesis



Precious3GPT


Multi Tissue Multispecies Multimomics Multimodal Life Model

Chemistry42



Generative Chemistry

Generate Novel Molecules




Alchemistry

Physics-based Relative Binding Free Energy Engine



ADMET & Off-target

On-the-fly Optimization




MDFlow

End-to-end simulation workflows




Retrosynthesis

Predict Synthetic Routes for Molecular Structures



Model Training

Train a State-of-the-art Model on the Data



MolSpace

Visualize the result of generations using GTM and compare it with the entirety of public data



Nach01

Multimodal Natural & Chemical Languages Foundation Model


Medicine42



inClinico

Design and Predict Clinical Trials

Science42



DORA


Multi-agent Generative Research Assistant



Science MMAI Gym

Boost the LLM's intelligence in drug discovery and development

AI Assistant



Copilot

Generative Conversational Agent



Environmental Sustainability



Generative AI Technologies for Environmental Sustainability



Data Warehouse

Seamless Cross-application Data Flow via Efficient Integration & Standardization

Insilico Generative AI for Drug Discovery Process: Code to Cure



Life Star 2: AI-Driven Automated Laboratory Accelerates Drug Discovery and Development

Target discovery
and target validation


Drug development and
translational medicine

Algorithm
validation

AI modules



pandaOmics

Chemistry42



Automation module

- ✓ Sample self-registration
- ✓ Compound management platform
- ✓ Cell culture platform
- ✓ High throughput screening platform
- ✓ High-connotation imaging platform
- ✓ Next generation sequencing platform






SECTION 3

Sources of Revenue

Multi-Pronged Revenue Generating Business Model for Long-term Growth



Drug Discovery and Pipeline Development

- **Generated 32** asset pipeline
- 17 out-licensing or collaboration deals with total contract value of **~US\$11 billion**
- In 2025, collaborated with **75 customers** for drug discovery business



Software Solutions



Biology42





Chemistry42



Medicine42



Science42



Other Discovery Related to Non-pharma Sectors

Utilize Pharma.AI to discover novel molecules for specific topics related to non-pharma industry

Accelerating the discovery of novel, environmentally friendly crop protection products that combat diseases, weeds, and pests while preserving ecosystems



Collaboration with a global energy company




Development of next-generation nutraceuticals **S | R | W***



Pharma.AI Proprietary Generative AI Platform

32 Asset Pipeline Discovered from Our Generative AI Platform with an Asset Most Advanced Globally among Peer Companies



Development Strategy

1



To Discover Novel Targets

2



Optimization on Existing Targets/Drugs

Therapeutic Pipeline


Therapeutic Pipeline			Stage of Development								
Program	Target	Indication	Target Identification	Target-to-hit	Hit-to-lead	Lead Optimization	IND-enabling	Phase 1	Phase 2	Phase 3	Partners
ISM001-055 (Rentosertib)	TNIK	IPF ⁽²⁾	China (NMPA) China Phase III Initiated								
		US (FDA)									
		IPF (Inhalable)	China (NMPA)								
ISM5411 (Garutadustat)	PHD1/2	IBD	China (NMPA) Australia & China Phase I Completed								
ISM4808		Anemia of Chronic Kidney Disease	China (NMPA)								Greater China rights out-licensed to TaiGen
ISM3091	USP1	BRCA-mutant Cancer	US (FDA)								EXELIXIS
ISM8207	QPCTL	Immuno-Oncology	China (NMPA)								FOSUN PHARMA 复星医药
ISM5043	KAT6	ER+/HER2- BC	US (FDA)								MENARINI group
ISM3412	MAT2A	MTAP ^{-/-} Cancer	US (FDA) & China (NMPA)								
ISM6331	TEAD	Mesothelioma and Solid Tumors ⁽²⁾	US (FDA) & China (NMPA)								
ISM9682	KIF18A	Solid Tumors	US (FDA)								MENARINI group
ISM8969	NLRP3	Parkinson's Disease, etc.	Australia (TGA)								Hygtia Therapeutics
ISM5059		Inflammatory Diseases									
ISM5939	ENPP1	Solid Tumors	US (FDA)								
Undisclosed	Nav1.8	Acute Pain and Chronic Pain									Greater China rights out-licensed to undisclosed partner
ISM3830	CBLB	Immuno-Oncology									
Undisclosed	GLP-1R	Metabolic Diseases									Global rights out-licensed to undisclosed partner
ISM0676	GIPR	Obesity & Metabolic Diseases									
ISM6166	Pan-KRAS	Solid Tumors with KRAS Aberrations									
Undisclosed	NR3C1	Metabolic Diseases and Oncology									
ISM0387	PRMT5	Glioblastoma	First PCC nominated in UAE								
ISM9528	Target Z	Pain									
ISM9077	Target Y	Eye diseases									
Undisclosed	Lp(a)	Metabolic Diseases									
Undisclosed	VAV1	Inflammatory Diseases									
Undisclosed	APJ	Obesity and Metabolic Diseases									

Notes:

- All programs are designed for oral administration unless otherwise indicated
- FDA granted ISM001-055 the orphan drug designation for its IPF indication and granted ISM6331 for Mesothelioma

Fibrosis Oncology Immunology Metabolic Others

Strong BD Momentum with Upfront and Milestones Continuously Realized



Out-licensing /
Co-development

EXELIXIS[®]

MENARINI
group

FOSUN PHARMA

Hygtia Therapeutics

Research
Collaboration

FOSUN PHARMA

sanofi

SERVIER[®]

CMS 康哲药业
CHINA MEDICAL SYSTEM

and more...

~\$11B Total contract value + Additional Royalties




>\$205M Revenue
realized by 2025*

~\$10.8B
Potential revenue in
the future

- ✓ XL309/ISM3091 (USP1) received \$80m upfront + \$10m milestone
- ✓ MEN2312/ISM5043 (KAT6) received \$12m upfront + milestone
- ✓ MEN2501/ISM9682 (KIF18A) received \$20m upfront + \$8m milestone
- ✓ Multiple collaborative R&D projects achieved milestones
- ...

* Drug Discovery and Pipeline Development revenue by 2025

Insilico Medicine Achieved Global AI-Driven R&D Collaboration with Lilly



✓ Exclusive worldwide license of potentially best-in-class, novel oral therapeutics in preclinical development for certain indications

✓ Collaborate on multiple R&D programs focused on targets selected by Lilly

The collaboration is a testament to:

1. High asset quality generated by Insilico's Pharma AI platform
2. Continued capability of Insilico's AI platform in development of novel therapeutics across multiple therapeutic areas
3. Demonstration of long-term partnership formation and growth from software, to strategic collaboration, to investment, to out-licensing and R&D collaboration

Upfront Payment
\$115M

Milestone Payments
Up to **\$2.64B**

Royalties

Total Deal Value
~\$2.75B

Multiple Out-Licensing Deals with Top Pharma and Biotech since 2021



2023

USP1
Out-licensing

Upfront payment **\$80 million**
plus milestones

Total deal value close to
\$1 billion plus royalties



2023

KAT6
Out-licensing

Upfront payment **\$12 million**
plus milestones

Total deal value over
\$500 million, plus royalties



2024

KIF18A
Out-licensing

Upfront payment **\$20 million**
plus milestones

Total deal value over
\$550 million, plus royalties



2025

PHD1/2
Greater China Rights
Out-licensing

Total deal value over **tens**
of millions of USD, plus
royalties

Hygtia
Therapeutics

2026

NLRP3
Co-development

Upfront payment **\$10 million**
plus milestones

Total deal value
\$66 million



2026

Molecule Out-licensing
& Research
Collaboration

Upfront payment **\$115**
million plus milestones

Total deal value near **\$2.75**
billion, plus royalties

Multiple R&D Collaboration with Top Pharma and Biotech since 2021

FOSUN PHARMA

2021

**QPCTL Co-development
& 4 Collaboration Targets**

Upfront of **\$13 million**
+ **\$15 million** equity
investment

Total deal value up to
\$82 million

sanofi

2022

**Up to 2 + 4
Collaboration Targets**

Upfront plus target nomination
fees of **\$21.5 million**

Total deal value up
to **\$1.2 billion**, plus royalties

Lilly

2025

Research Collaboration

Total deal value over
\$100 million,
plus royalties

SERVIER

2026

Research Collaboration

Upfront and near-term R&D
payments **\$32 million** plus
milestones

Total deal value over
\$888 million, plus royalties

TENACIA

2026

Research Collaboration

Total deal value near
\$100 million

齐鲁制药
QILU PHARMACEUTICAL

2026

Research Collaboration

Total deal value near
\$120 million,
plus royalties

CMS 康哲药业
CHINA MEDICAL SYSTEM

2026

Research Collaboration

Up to **tens of millions of
HKD** per project in R&D
support

SK biopharmaceuticals

2026

Research Collaboration

Up to **\$18 million** in upfront
and near-term milestones

Total deal value exceeds **\$2.5
billion**, plus royalties

Takeda

2026

Research Collaboration

Up to **\$60 million** in upfront
and near-term milestones

Total deal value exceeds **\$600
million**, plus royalties

CMS 康哲药业
CHINA MEDICAL SYSTEM

2026

Research Collaboration

Total deal value up to **1.2
billion RMB**, plus royalties

Multiple R&D Collaboration with Top Pharma and Biotech since 2021 (Con't)



2026

Strategic Alliance

Potential value of the proposed collaboration could exceed **\$2.5 billion**


MMAI Gym: Where AI Trains for Science

A complete training ecosystem that transforms any LLM into a domain-specific scientific reasoning engine



6 Scientific Domains

Chemistry, Biology, Clinical, Aging/Longevity, Materials Science, Agriculture




500M+ Data Samples

across diverse curated data sources




1000+ Benchmarks

400+ *in vitro* PD, 100+ *in vivo* PD, 30+ DMPK, 40+ toxicology/selectivity



300+ Reasoning Datasets

featuring deep reasoning traces and high-fidelity sample datasets



700+ Curated Diseases

across all therapeutic areas



Proprietary metrics

ChemCensor™ plausibility scoring, Solvability+, Clinical Target Retrieval@K

Proprietary data + training infrastructure

that teaches LLMs domain-specific scientific reasoning via SFT + reinforcement fine-tuning (RFT)

Covers full drug discovery pipeline

target ID, molecular generation, ADMET prediction, retrosynthesis, clinical trial outcome forecasting, and aging research

Models become fluent in domain formats

including SMILES, 3D molecular structures, protein sequences, and specialized scientific tokens

Achieves SOTA without any tool calls

models internalize domain knowledge and solve complex tasks by decomposing into relevant subtasks autonomously

Works with any Causal LM

on HuggingFace Transformers: customer brings their base model, Insilico provides data + training

MMAI Gym: Towards Chemical and Biological Superintelligence

After MMAI Gym training, foundation models can achieve up to 10-fold performance gains on key drug discovery benchmarks, compared to their baseline performance where they fail on approximately 75–95% of tasks.

Foundation models trained at the Gym demonstrated substantial gains on Target Search Benchmarks

Qwen3-4B outperformed all frontier foundation models in the retrieval of clinical targets after one training session at the MMAI Gym




Figure 1. Metrics on the TargetBench benchmark*

Foundation models trained at the Gym demonstrated substantial gains on Chemical Synthesis Benchmarks

Liquid AI Model (LFM2-2.6B) outperformed all frontier foundation models and model-specialists in single-step retrosynthesis after training at the MMAI Gym

After AI Gym		Conventional SSRS models							
	Liquid AI model 2 - MMAI	LocalRetro	RetroKNN	Graph2Edits	R-SMILES	MHNreact	MEGAN	GLN	Chemformer
[1]	2.16	2.14	2.13	2.11	2.10	2.08	2.03	1.97	1.77
[2]	1.90	1.87	1.86	1.81	1.87	1.86	1.76	1.73	1.02

	Gemini 3.1 Pro	Grok 4.1	Kimi K2.5	Claude 4.6 Opus	Qwen 3.5	GLM 5	Claude 4.6 Sonnet	GPT 5.2	MiniMax M2.5	DeepSeek 3.2	Liquid AI 2
[1]	1.96	1.90	1.73	1.73	1.57	1.50	1.26	0.85	0.64	0.51	0.00
[2]	1.72	1.59	1.42	1.39	1.08	1.06	0.77	0.47	0.28	0.35	0.00

| Frontier Foundation Models | | | | | | | | | | | |
| Before AI Gym | | | | | | | | | | | |

[1] Average CC per target, Max CC


[2] Average CC per target, Top-3 CC

Figure 2. Metrics on the URSA-expert-2026 benchmark**

* <https://doi.org/10.1101/2025.08.06.668866>

** <https://arxiv.org/abs/2602.03554>

Science MMAI Gym Business Flow




SECTION 4

Pipeline Details




Case Study: ISM001_055 (TNIK Inhibitor) is the Most Clinically Advanced AIDD Candidate Globally



- ✓ Potent ATP competitive TNIK inhibitor
- ✓ Binds to TNIK with a high affinity, $K_D=4.32$ nM
- ✓ Inhibits TNIK and other fibrogenic kinases



Targeting TNIK, Rentosertib inhibits:

- ✓ TGF- β dependent fibrogenesis, and EMT (epithelial mesenchymal transition) / FMT (fibroblast-to-myofibroblast transition)
- ✓ NF- κ B signal pathway leading to anti-inflammation
- ✓ Downstream genes/interacting partners of YAP/TAZ, which are reported to promote fibrosis



Ren et al. *Nat Biotech* **2024**; 43: 56-75

ISM001-055 Out-performs Other Investigational Agents in Cross Trial Data Comparison




Source: Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022). Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. *New England Journal of Medicine*, 386(23), 2178–2187. <https://doi.org/10.1056/nejmoa2201737>; Maher TM, Hamblin MJ, Choi WI, et al. Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): A phase 2b randomized placebo-controlled trial. *Am J Respir Crit Care Med*. 2026. doi:10.1093/ajrccm/aamag155; FDA approved drug label; Boehringer Ingelheim website; United Therapeutics website; Sunshine Lake Pharma 2025 Annual Report.

Note:
1. One outlier was noted: One outlier was randomized to the placebo treatment group and excluded from the analysis.
2. Treprostinil data are estimated from the published Phase 3 results figure.

Phase III Trial GENESIS-IPF-3 Positioned to Confirm Rentosertib's Efficacy and Safety for IPF Patients

Key inclusion

- Age ≥ 40 y
- IPF diagnosis
- FEV1/FVC > 0.7
- FVC $\geq 40\%$ predicted
- $25\% \leq \text{DLCO} < 80\%$
- $\pm$ Stable antifibrotic SOC treatment




Primary endpoint

Change from baseline in Forced Vital Capacity (FVC) (mL) over 52 weeks

- Participants are allowed to continue with background anti-fibrotic medication
- FPI in 2026 and topline data expected by 2029

DLCO, diffusing capacity of the lungs for carbon monoxide; HBcAb, hepatitis B core antibody; HBV, hepatitis B virus; IPF, idiopathic pulmonary fibrosis; FEV1, Forced Expiratory Volume in 1 second; QD, once daily; SOC, standard of care.

Garutadustat: Potential First-in-Class Gut-Restricted HIF-PHD Inhibitor for IBD



- ✓ Orally gut-restricted exposure
 - High colon/plasma ratio
 - High distribution in colon compared to systemic compartment
- ✓ Anti-inflammation and epithelial barrier repair
- ✓ Expected to alleviate UC or gut associated symptom of CD
- ✓ Development status: Phase I studies completed in Australia and China; Phase IIa study ongoing

Gut-restricted prolyl hydroxylase (PHD) inhibitor garutadustat stabilizes HIF-1 α protein and drives intestinal barrier protection





Figure adapted from Van Welden S, et al. Nat Rev Gastroenterol Hepatol 2017;14:596–611.

Garutadustat Phase IIa BETHESDA Study: Barrier Enhancement Therapy for Healing Enteric Structural Defects & Anomalies

- Garutadustat is a potential first-in-class gut-restricted HIF-PHD inhibitor for IBD
- Completed Phase 1 trial in Australia (N=76) and China (N=48)
- Phase IIa trial in China started from December 2025

Key inclusion

- Patients with active ulcerative colitis
- Stable dose of background therapy including
- Oral 5-aminosalicylic acid (5-ASA) $\pm$ glucocorticoids



Key endpoints

Primary: Safety and tolerability


Secondary: Plasma/colonic PK profiles

Exploratory:

- Clinical remission/clinical response
- Endoscopic improvement/mucosal healing/histologic remission
- Change of biomarkers

FPI completed in Dec 2025
Topline data expected by 2027

ISM6331: Potential Best-in-class Pan-TEAD Inhibitor Targeting the Hippo Pathway



Mechanism and Market Gap

NF2 loss / LATS1/2 mutations



Addresses unmet need in ~40%
of Malignant Mesothelioma,
alongside NSCLC/SCLC subsets.

Crucial market gap:
No currently approved therapies
target this nodal dependency.

The PK to Patient Value Chain




Favorable ~21h half-life
successfully avoids the 7-10x
accumulation seen in earlier
class agents.

Eliminates the need
for complex, intermittent
'on/off' cycling regimens.

Dramatically improves patient
compliance, making it an
ideal candidate for long-term
combination therapy

Evaluation Dimension	ISM6331 Profile	Historical Class Hurdles
Mechanism	Broad Pan-TEAD Coverage	Weak TEAD4 or isolated TEAD1 activity
Safety Profile	Clear safety margin, well-tolerated (cleared 4 dose cohorts)	Terminated due to QTc prolongation, severe proteinuria, and DDI risks
Dosing Regimen	Continuous QD (Once Daily)	Intermittent (e.g., 2 weeks on/off) due to extreme accumulation

ISM6331 Enters a High-value De-risking Period with Confirmed Clinical Efficacy and Near-term Catalysts



Early Clinical Validation

Confirmed Efficacy Signal

Confirmed PRs and high disease control rates observed in heavily pre-treated Mesothelioma patients (4-5 prior lines of therapy). Broad anti-tumor activity confirmed.

Favorable Safety Confirmation

Favorable tolerability profile maintained; ongoing clinical dose escalation has successfully cleared four cohorts with treatment-related adverse events strictly limited to Grade 1.

Strategic Combination Backbone

Standard of Care Integration

Strong potential as a backbone alongside **EGFR inhibitors (e.g., Tagrisso) or ADCs or KRAS inhibitors** to prevent bypass resistance.

The 'Double-Clamp' Synergy

Potential of Hippo and metabolic pathway combinations. Combining ISM6331 with our MAT2A inhibitor (ISM3412) to secure an exclusive, first-in-class niche targeting Mesothelioma and MPNST.

Ongoing

2H 2026

4Q 2026 / 1Q 2027

Phase 1 Dose Escalation

Generating broad anti-tumor activity and safety data.

Scientific Congress

Detailed clinical efficacy and quantitative dose-escalation data to be submitted for presentation.

Part 2 Dose Optimization

Progressing to refine the registrational dose and confirm expanded efficacy signals.

ISM6166: An Orally Available Pan-KRAS (ON/OFF) Inhibitor

Target KRAS alterations in both ON/OFF states

- ✓ High binding affinity for both GDP- and GTP-bound KRAS proteins
- ✓ Address all major KRAS alterations including G12C, G12D, G12V and WT amp



High selectivity over HRAS/NRAS

- ✓ Spare essential HRAS and NRAS with >100x selectivity to avoid potential AEs
- ✓ >10x higher selectivity than **RMC-6236** in KRAS-independent or non-cancerous cells

Balanced Druggability profile


- ✓ Decent PK profile across preclinical species with CL<Qh and double-digit bioavailability
- ✓ Balanced properties enable better *in vivo* efficacy than **other pan-KRAS inhibitors**

KRAS Mutation Landscape




Superior *in vivo* efficacy




MKN-1 (Gastric, KRAS WT^{amp})



NCI-H441 (Lung, KRAS^{G12V})



Insilico Medicine Comprehensive Oncology Portfolio with Extensive Combination Opportunities




Highlight of Metabolic Disease Programs in Post-Incretin Era

Preserve muscle while reducing fat


Potential Best-in-Class GIPR antagonist

- ✓ Dose-dependent synergy for achieving a breakthrough beyond the GLP-1RA weight loss plateau
- ✓ Improved lean mass-to-body weight ratio
- ✓ Reduced DDI risk
- ✓ Excellent DMPK profile




G protein biased APJ agonist


- ✓ PO administration
- ✓ Greater body weight loss
- ✓ Increased lean mass to body weight ratio when combo with Semaglutide




ISM9528: AI-powered Target Identification for Pain



ISM9528: AI-enabled Compound Generation and Optimization







Insilico
Medicine



In Vivo Efficacy of ISM9528 in Preclinical Pain Models via oral or i.v routes


Novel target Z inhibitor ISM9528 demonstrated

- ✓ Dose-dependent analgesic effect
- ✓ Rapid onset and better efficacy than pregabalin and VX-548 *via* oral administration
- ✓ Long-lasting effect than morphine *via* intravenous administration




Targeted Protein Degradation Strategy in Inflammatory & Autoimmune diseases


IRAK4: Inhibition is not enough




VAV1: Dual-Pathway Signaling



STAT6 Protac- oral Dupilumab strategy




Superior efficacy to KT474, the most advanced IRAK4 protac molecule




Potential Best-In-Class VAV1 molecular glue

- ✓ specific target degradation
- ✓ superior efficacy in multiple disease models




Highly potent and selective STAT6 protac




NLRP3 Inhibitor – “One Drug Pipeline”

MPTP induced PD model



Significant dose-dependent efficacy in Parkinson’s disease mouse models.


Significantly accelerates wound healing and shows a synergistic effect with dapagliflozin in the STZ-induced diabetic foot-ulcer mouse model.




Significantly reduced pericardial effusion and pericardial thickness in the Zymosan-induced pericarditis model.

Improved visual acuity via oral dosing or eye-drop administration in the dry AMD model, with efficacy surpassing that of the positive control.


STZ induced foot ulcer model



Zymosan induced pericarditis model




NaIO₃ induced dry-AMD model




Target Y – First-in-class Program as Next Generation “One Drug Pipeline”

Number of Iba1⁺ cells in SN



Distance in open field after MPTP injection in mice



Significant dose-dependent efficacy in mice Parkinson's disease models

Ameliorated in histopathology and vision acuity via oral dosing in dry AMD model

Parkinson




Dry AMD



Obesity



MASH






Target Y inhibitor in DIO mice



- ✓ Alone reduced body weight and improved insulin resistance
- ✓ Combination with Semaglutide further reduced body weight;
- ✓ Inhibited body weight rebounding after discontinuation of Semaglutide.

- Vehicle BID (n=7)
- 50mpk Target Y inh. BID (n=7)
- Sema 2.5nmol/kg+Vehicle BID (n=6)
- Sema 2.5nmol/kg+50mpk Target Y inh. BID (n=7)

- Sema 2.5 nmol/kg s.c. QD (D0-D10); n=4
- Target Y inh. 50mpk p.o. BID (D0-D10) + Sema 2.5 nmol/kg s.c. QD (D0-D10); n=4
- Target Y inh. 50mpk p.o. BID (D0-D29) + Sema 2.5 nmol/kg s.c. QD (D0-D10); n=4



In MASH mice model, Target Y inhibitor alone or in combination with TZIP (Tirzepatide) led to significant weight loss and mitigated MASH histopathology and fibrosis.



2026 Key Milestones Across both the Platform and Therapeutic Pipeline



Pipeline Development

2026 1H

- ✓ Rentosertib (Inhalable) IND approval for the treatment of IPF in China
- ✓ ISM8969 (NLRP3) FPI of Ph1 trial in Australia

2026 2H

- ISM6331 (TEAD) preliminary safety, efficacy, and biomarker data from Ph1 trial
- Rentosertib Ph3 trial initiation and FPI in China
- ISM8969 (NLRP3) IND approval for Ph1 trial in China
- ISM3412 (MAT2A) LPI for dose escalation part of Ph1 trial
- ISM6331 (TEAD) LPI for dose escalation part of Ph1 trial



Multiple new PCC + Multiple IND



Continue to achieve new BD deals

AI Platform

Quarterly Pharma.AI day to unveil new Gen-AI platform



Continue to execute MMAI Gym collaborations